Phaseline

Targets › F2R

F2R (Proteinase-activated receptor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Mar 2027.

High affinity receptor that binds the activated thrombin, leading to calcium release from intracellular stores. The thrombin-activated receptor signaling pathway is mediated through PTX-insensitive G proteins, activation of phospholipase C resulting in the production of 1D-myo-inositol 1,4,5-trisphosphate (InsP3) which binds to InsP3 receptors causing calcium release from the stores (By similarity). (UniProt, P25116)

Open in Phaseline: the race on F2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhujiang HospitalNafamostat Mesilate
Serine protease inhibitor; anticoagulant
F2, F2R, PLAUPhase 2Continuous Renal Replacement Therapy (CRRT)Mar 2027

Conditions

Continuous Renal Replacement Therapy (CRRT) (1)

Modalities

small molecule (1)

Companies

Zhujiang Hospital (1)

Related targets

F2 (1) PLAU (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.